Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$638.00K$638.00Kderived−90.9% vs Q4 2023 Net Income-$17.75M-$17.75MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$24,846,000N/M Operating Cash Flowderived-$18,683,000N/M Free Cash Flowderived-$18,780,000N/M Margins · derivedOperating margin-3894.4%−3682.8 pt vs Q4 2023
Net margin-2781.3%−2549.9 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 26, 2025 · 85 d after period end